Phospho-SMAD1 (S465) Antibody

What is the biological significance of SMAD1 phosphorylation at S465?

SMAD1 functions as a transcriptional modulator that plays crucial roles in embryonic development, cell differentiation, and tissue homeostasis. Phosphorylation at S465 (often coupled with S463 phosphorylation) is a critical regulatory event in the BMP signaling pathway. When BMP ligands bind to their cell surface receptors, activated type I BMP receptors (BMPRIs) phosphorylate SMAD1 at the S465 site. This phosphorylation enables SMAD1 to associate with SMAD4, forming a heteromeric complex that translocates to the nucleus and acts as a transcription factor. The complex recognizes cis-regulatory elements containing Smad Binding Elements (SBEs) to modulate gene expression .

How do SMAD1, SMAD5, and SMAD9 phosphorylation sites relate to each other?

SMAD1, SMAD5, and SMAD9 (formerly SMAD8) are highly homologous proteins belonging to the BMP-specific receptor-regulated SMADs (R-SMADs). These proteins share conserved phosphorylation sites:

While these sites are similarly regulated, research often requires distinguishing between these homologs. Phosphorylation at these conserved serine residues serves as the activation switch for all three proteins, enabling their participation in transcriptional regulation . Some antibodies recognize the phosphorylated forms of all three proteins due to the high sequence homology at these sites.

What are the recommended applications and dilutions for Phospho-SMAD1 (S465) antibody in various experimental techniques?

Based on validated technical data, the following applications and dilutions are recommended:

For optimal results, always validate these dilutions for your specific experimental system and antibody source .

How can I design experiments to simultaneously measure total SMAD1 and phosphorylated SMAD1?

For comprehensive analysis of SMAD1 activation status, simultaneous detection of total and phosphorylated protein is essential. Two primary approaches are recommended:

• Sequential immunoblotting on the same membrane:

  • First probe with phospho-specific antibody

  • Strip the membrane using a validated stripping buffer

  • Re-probe with total SMAD1 antibody

  • Calculate the phospho/total ratio for quantitative assessment

• Cell-based ELISA approach:

  • Use specialized kits designed for dual detection

  • Results are normalized to cell number

  • Provides quantitative measurement of relative phosphorylation levels

  • Eliminates the need for lysate preparation and western blotting

The Cell-Based ELISA method offers higher throughput capabilities and can detect endogenous levels of both total and phosphorylated protein in fixed cells, making it ideal for signaling kinetics studies .

How can I use Phospho-SMAD1 (S465) antibodies to study BMP pathway dynamics in real-time?

For studying the temporal dynamics of SMAD1 phosphorylation in response to BMP signaling:

• Time-course experiments:

  • Treat cells with BMP ligands (e.g., BMP2) at different time points

  • Use western blotting to track phosphorylation kinetics

  • Example protocol: Treat HEK293 cells with BMP2, then collect lysates at 15 min, 30 min, 1h, 3h, 6h, and 24h intervals

  • Compare phosphorylation levels across time points to determine activation patterns

• Proximity Ligation Assay (PLA):

  • Allows visualization of individual phosphorylated proteins in situ

  • Use antibody pairs (one against total SMAD1, one against phospho-S465)

  • Each red dot in the fluorescent image represents a single phosphorylated protein

  • Quantitative analysis can be performed using specialized software like BlobFinder

  • Provides spatial information about phosphorylation events within cells

• Pathway modulation:

  • Use pathway inhibitors (e.g., dorsomorphin) to block BMP receptor kinase activity

  • Apply pathway activators at different concentrations to establish dose-response relationships

  • Monitor changes in phospho-SMAD1 levels to assess pathway modulation efficacy

What experimental models are most suitable for studying SMAD1 phosphorylation in developmental contexts?

Based on research using phospho-SMAD1 antibodies, these models have proven valuable:

These models provide physiologically relevant contexts for studying developmental roles of SMAD1 phosphorylation in processes like osteogenesis, chondrogenesis, and tissue homeostasis.

How can I validate the specificity of my Phospho-SMAD1 (S465) antibody?

Validating antibody specificity is critical for reliable experimental results. Recommended validation approaches include:

• Peptide competition assay:

  • Pre-incubate the antibody with immunizing phosphopeptide (positive control)

  • Pre-incubate with corresponding non-phosphopeptide (negative control)

  • Use in parallel western blots to confirm specific blocking by phosphopeptide only

  • Example: BMP2-treated HEK293 cell lysates show blocked detection with phosphopeptide but not with non-phosphopeptide

• Pathway modulation controls:

  • Use BMP treatment (e.g., BMP2) to induce phosphorylation (positive control)

  • Use pathway inhibitors to block phosphorylation (negative control)

  • Compare band intensity in western blots to confirm specificity

• Knockout/knockdown validation:

  • Use SMAD1 knockout or knockdown cells/tissues

  • Absence of signal confirms antibody specificity

  • Cross-reactivity with other SMADs can be assessed in this system

Why might I observe differences in molecular weight for phosphorylated SMAD1 across different experimental systems?

Researchers frequently observe phospho-SMAD1 at apparent molecular weights between 52-60 kDa, despite the calculated molecular weight of 52 kDa. This discrepancy is attributed to several factors:

• Post-translational modifications:

  • Phosphorylation at multiple sites

  • Other modifications like ubiquitination or SUMOylation

  • These can alter protein migration in SDS-PAGE

• Experimental conditions:

  • Different gel concentrations affect migration patterns

  • Running buffer composition influences apparent molecular weight

  • Sample preparation methods (reducing vs. non-reducing conditions)

• Tissue/cell-specific differences:

  • Cell-type specific modifications

  • Species-specific variations in SMAD1 processing

For example, western blot analysis with NIH/3T3 cells showed phospho-SMAD1 at approximately 60 kDa, whereas the predicted size is 52 kDa . When comparing results across studies, these variations should be considered normal and not necessarily indicative of antibody specificity issues.

How can Phospho-SMAD1 antibodies be used in chromatin immunoprecipitation (ChIP) studies?

Phosphorylated SMAD1 functions as a transcription factor, making ChIP an important technique for studying its genomic targets:

• Protocol considerations:

  • Use antibodies validated specifically for ChIP applications

  • Optimize crosslinking time (typically 10-15 minutes with 1% formaldehyde)

  • Sonication parameters should be carefully calibrated to generate 200-500bp fragments

  • Include appropriate controls (IgG negative control, input control)

• Research applications:

  • Identify direct genomic targets of activated SMAD1

  • Study temporal dynamics of SMAD1 binding to enhancers/promoters

  • Investigate cooperation with other transcription factors

• Analysis approaches:

  • ChIP-seq for genome-wide binding profiles

  • ChIP-qPCR for targeted analysis of specific regulatory regions

  • Integration with RNA-seq data to correlate binding with gene expression changes

What are the methodological considerations for studying cross-talk between SMAD1 phosphorylation and other signaling pathways?

SMAD1 phosphorylation integrates with multiple signaling networks. To study these interactions:

• Dual pathway activation experiments:

  • Simultaneously activate BMP and complementary pathways (e.g., WNT, FGF)

  • Measure changes in SMAD1 phosphorylation status

  • Use phospho-specific antibodies to multiple sites (linker region vs. C-terminal)

• Inhibitor studies:

  • Apply pathway-specific inhibitors (e.g., dorsomorphin for BMP, U0126 for MEK/ERK)

  • Monitor effects on SMAD1 phosphorylation at S465 vs. other sites

  • Establish hierarchical relationships between pathways

• Phosphorylation site analysis:

  • Use antibodies specific to different phosphorylation sites

  • Compare dynamics of C-terminal (S463/S465) vs. linker region phosphorylation

  • Correlate with cellular outcomes (differentiation, proliferation, etc.)

For example, UV treatment of A549 cells showed temporal regulation of SMAD1 phosphorylation during different repair periods, suggesting cross-talk with DNA damage response pathways .